期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
FLT-PET监测靶向治疗ALK阳性淋巴瘤早期疗效优于FDG-PET 被引量:2
1
作者 李周雷 ken herrmann Alexandra Juenger 《影像诊断与介入放射学》 2019年第1期70-74,共5页
复发的侵袭性淋巴瘤一般预后较差,靶向药物治疗成为当今肿瘤学研究的热点。准确指示癌症对治疗早期反应的影像学方法会大大提高对靶向药物治疗的效率。使用各种ALK阳性间变性大细胞淋巴瘤(ALCL)细胞系来评估靶向药物(HSP90抑制剂NVP-AUY... 复发的侵袭性淋巴瘤一般预后较差,靶向药物治疗成为当今肿瘤学研究的热点。准确指示癌症对治疗早期反应的影像学方法会大大提高对靶向药物治疗的效率。使用各种ALK阳性间变性大细胞淋巴瘤(ALCL)细胞系来评估靶向药物(HSP90抑制剂NVP-AUY922和m TOR抑制剂癌伏妥)的早期疗效,两者都显示出具有干扰ALK依赖性致癌信号转导的功能。细胞实验中使用MTT、示踪剂摄取及其他生化试验来分析ALK诱导的信号传导。另外,对ALCL异种移植物小鼠行FDG和FLT-PET,评估NVP-AUY922或依维莫司在体内的早期治疗反应。结果显示SUDHL-1细胞对两种抑制剂的干预敏感;早在治疗开始5 h时FLT摄取就有明显降低。病理检测显示Ki-67表达减少,而caspase-3的表达增加。但FDG摄取在治疗早期无显著变化。Karpas299细胞对NVP-AUY922的治疗具有抗性,对依维莫司治疗敏感。在施用治疗后第2天NVP-AUY299干预组的FLT摄取依旧增加,癌伏妥治疗组的FLT摄取显著降低。FLT-PET能在靶向治疗早期就预测淋巴瘤对治疗的反应,对早期疗效的预测FDG-PET比FLT-PET略差。 展开更多
关键词 FLT-PET 靶向治疗 早期监测 间变型大细胞淋巴瘤
下载PDF
Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters 被引量:4
2
作者 Hinrich A Wieder Michael Lassmann +2 位作者 Martin S Allen-Auerbach Johannes Czernin ken herrmann 《World Journal of Radiology》 2014年第7期480-485,共6页
Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer.Different radionuclides that emitβ-rays such as 153Samarium and 89Strontium and ach... Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer.Different radionuclides that emitβ-rays such as 153Samarium and 89Strontium and achieve palliation are commercially available.In contrast toβ-emitters,223Radium as a a-emitter has a short path-length.The advantage of the a-emitter is thus a highly localized biological effect that is caused by radiation induced DNA double-strand breaks and subsequent cell killing and/or limited effectiveness of cellular repair mechanisms.Due to the limited range of the a-particles the bone surface to red bone marrow dose ratio is also lower for 223Radium which is expressed in a lower myelotoxicity.The a emitter 223Radium dichloride is the first radiopharmaceutical that significantly prolongslife in castrate resistant prostate cancer patients with wide-spread bone metastatic disease.In a phaseⅢ,randomized,double-blind,placebo-controlled study 921patients with castration-resistant prostate cancer and bone metastases were randomly assigned.The analysis confirmed the 223Radium survival benefit compared to the placebo(median,14.9 mo vs 11.3 mo;P<0.001).In addition,the treatment results in pain palliation and thus,improved quality of life and a delay of skeletal related events.At the same time the toxicity profile of223Radium was favourable.Since May 2013,223Radium dichloride(Xofigo?)is approved by the US Food and Drug Administration. 展开更多
关键词 RADIUM Bone targeted radiopharmaceuticals Alpha emitters
下载PDF
Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [<sup>18</sup>F]Fluorothymidine-PET 被引量:1
3
作者 Nicolas Graf Zhoulei Li +8 位作者 ken herrmann Michaela Aichler Jolanta Slawska Axel Walch Christian Peschel Markus Schwaiger Andreas K. Buck Tobias Dechow Ulrich Keller 《Advances in Molecular Imaging》 2015年第2期17-28,共12页
Background: Inhibition of the lymphoma surface antigen CD40 by the antagonistic CD40 antibody NVP-HCD122 (HCD122) demonstrates activity in various lymphoma subtypes. In this preclinical in vivo study we examined the s... Background: Inhibition of the lymphoma surface antigen CD40 by the antagonistic CD40 antibody NVP-HCD122 (HCD122) demonstrates activity in various lymphoma subtypes. In this preclinical in vivo study we examined the suitability of positron emission tomography (PET) using the thymidine analogue 3’-deoxy-3’-[18F]fluorothymidine (FLT) for early response assessment upon HCD122 treatment in diffuse large B cell lymphoma (DLBCL). Methods: Immunodeficient mice bearing human DLBCL xenografts (SU-DHL-4) received weekly intraperitoneal injections of HCD122. Tumor growth was followed up until Day 14. Molecular imaging with FLT-PET was performed before (Day 0) and after start of therapy (Day 2 and Day 7). On Day 14 lymphoma xenografts were explanted for immunohistochemical analysis to correlate PET findings with CD40 surface expression on tumor tissue. Results: Treatment with HCD122 significantly delayed tumor growth resulting in a tumor growth inhibition of 45% on Day 14. Significant reduction of tumor-to-background ratio (TBR) of FLT-PET was seen in treated animals on Day 7 and preceded change of tumor volume, thus predicting therapy response to HCD122. Immunohistochemical analysis of xenografts revealed significantly higher CD40 expression on treated than on untreated tissue. Moreover, we found a significant correlation between CD40 expression and FLT-PET response for xenograft tumor treated with HCD122. Conclusions: Treatment of DLBCL with the antagonistic CD40 antibody HCD122 can be monitored with FLT-PET as early as seven days after commencement of therapy and seems to increase CD40 expression on tumor tissue. 展开更多
关键词 CD40 Antibody FLT-PET LYMPHOMA Therapy Monitoring
下载PDF
^18F-FDG PET/CT和PET/MR在恶性肿瘤中的应用价值相仿:2300余例患者的临床研究总结 被引量:4
4
作者 刘国兵(译) 石洪成(审校) +2 位作者 Claudio Spick ken herrmann Johannes Czernin 《中华核医学与分子影像杂志》 CAS 北大核心 2020年第4期247-256,共10页
^18F-脱氧葡萄糖(FDG) PET/CT已成为恶性肿瘤影像学评估的参考标准.PET/MR的优势在于通过多参数影像进一步提高对恶性肿瘤诊断的准确性和肿瘤特征的识别;也有学者探讨了^18F-FDG PET结合MRI提供的精细解剖信息是否提升了肿瘤分期和再分... ^18F-脱氧葡萄糖(FDG) PET/CT已成为恶性肿瘤影像学评估的参考标准.PET/MR的优势在于通过多参数影像进一步提高对恶性肿瘤诊断的准确性和肿瘤特征的识别;也有学者探讨了^18F-FDG PET结合MRI提供的精细解剖信息是否提升了肿瘤分期和再分期的准确性.该文首先介绍了PET/MR的结构、成像参数和机器操作方面的内容,后综述现有文献,分析了PET/MR对于恶性肿瘤的评估是否具有增益价值.现有数据分析结果显示,PET/MR适用于大多数类型的恶性肿瘤,其效能与PET/CT相当.PET/MR的优势应用领域主要体现在对前列腺癌和骨转移肿瘤的诊断,非优势应用领域是肺内病变的评估.因此,当MRI仅用于提供病灶解剖结构时,PET/MR和PET/CT对于恶性肿瘤的诊断价值相当.如果检查费用经济可行、且检查流程规范,PET/MR可以代替PET/CT.MRI多参数成像的潜在价值需要更多的临床研究和探索. 展开更多
关键词 PET/CT PET/MR 肿瘤学 癌症诊断 分期 疗效监测
原文传递
177Lu-PSMA放射性配体在前列腺癌治疗中的应用 被引量:1
5
作者 王帅亮(译) 杨卫东 +5 位作者 汪静(审校) Wolfgang P. Fendler Kambiz Rahbar ken herrmann Clemens Kratochwil Matthias Eiber 《中华核医学与分子影像杂志》 CAS 北大核心 2019年第10期636-640,共5页
利用前列腺特异膜抗原(PSMA)抑制剂进行177Lu-PSMA放射性配体治疗(RLT)是针对转移性去势抵抗性前列腺癌(mCRPC)患者的一种新型治疗模式。研究表明,该疗法行之有效且患者耐受性好。基于临床需求和现有研究依据,该疗法已在全球范围内的多... 利用前列腺特异膜抗原(PSMA)抑制剂进行177Lu-PSMA放射性配体治疗(RLT)是针对转移性去势抵抗性前列腺癌(mCRPC)患者的一种新型治疗模式。研究表明,该疗法行之有效且患者耐受性好。基于临床需求和现有研究依据,该疗法已在全球范围内的多个医疗中心付诸实施。该文对177Lu-PSMA的RLT的几个重要方面进行综述,包括患者分级分期、治疗方案、合并用药、患者随访等,旨在对参与RLT的医务工作者和mCRPC患者提供指导。 展开更多
关键词 肿瘤 放射疗法 放射性同位素 辐射增敏药 纳米结构 发展趋势
原文传递
神经内分泌肿瘤68Ga-DOTATATE显像新观点:图像解读、体内分布、辐射内照射剂量及分子机制 被引量:1
6
作者 胡桂兰 庞芮(译) +4 位作者 霍力(审校) Lisa Bodei Valentina Ambrosini ken herrmann Irvin Modlin 《中华核医学与分子影像杂志》 CAS 北大核心 2019年第8期504-512,共9页
利用68Ga-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽(DOTATATE)PET/CT显像对表达生长抑素受体(SSTR)的肿瘤进行定位,就必须将图像信息有效地与患者诊疗过程相结合,包括临床病史、组织病理学、生物... 利用68Ga-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽(DOTATATE)PET/CT显像对表达生长抑素受体(SSTR)的肿瘤进行定位,就必须将图像信息有效地与患者诊疗过程相结合,包括临床病史、组织病理学、生物标志物、肿瘤分期和分级以及已知的影像学检查结果,另外还要考虑到患者已完成的治疗及检查对68Ga-DOTATATE图像的影响(如影响正常生理性分布并导致假阳性结果)。该文针对68Ga-DOTATATE PET/CT显像在图像采集、分析、神经内分泌肿瘤诊断方案及治疗中的价值提供指导意见。 展开更多
关键词 内分泌 神经内分泌 肿瘤学 68Ga-DOTATATE 生物分布
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部